| Q50504071 | Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. |
| Q50439428 | Clinicopathological significance of sentinel node biopsy in Japanese patients with cutaneous malignant melanoma |
| Q33705837 | Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care? |
| Q49264293 | Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long-term follow-up |
| Q50519176 | Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. |
| Q73829724 | Limitations of vital dye in selective biopsy of sentinel lymph node for melanoma |
| Q46460258 | Lymphatic mapping and sentinel lymphadenectomy for melanoma |
| Q33932031 | Melanoma. A multidisciplinary approach for the general surgeon |
| Q77594538 | Minimal access surgery for staging regional lymph nodes: the sentinel-node concept |
| Q47658252 | Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit. |
| Q35545019 | Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma |
| Q50522349 | Sentinel node biopsy: a revolution in the surgical management of breast cancer? |
| Q36624158 | Sentinel node detection in N0 cancer of the pharynx and larynx |
| Q50510392 | Successful mapping of lymphorrhea using patent blue dye after lymph node dissection for malignant melanoma. |
| Q33828582 | The concept of sentinel node localization: how it started |
| Q33828587 | The pathologist's role in sentinel lymph node evaluation |
| Q34120222 | The role of sentinel lymph nodes in malignant melanoma |
| Q47258161 | The sentinel node concept in head and neck cancer: solution for the controversies in the N0 neck? |
| Q50204442 | Use of indirect lymphography to identify sentinel lymph node in dogs: a pilot study in 30 tumours |
| Q77122627 | Value of sentinel lymphonodectomy in head and neck cancer patients without evidence of lymphogenic metastatic disease |